Which has higher valuation and earnings, QTRX or SIBN?

SiBone has higher revenue and earnings than Quanterix. SiBone is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix $138.90M 1.04 -$107.15M -$2.36 N/A SiBone $200.93M 3.39 -$18.90M -$0.39 N/A

Is QTRX or SIBN more profitable?

SiBone has a net margin of -8.10% compared to Quanterix's net margin of -71.86%. SiBone's return on equity of -9.56% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -71.86% -23.92% -17.66% SiBone -8.10% -9.56% -7.06%

Does the media refer more to QTRX or SIBN?

In the previous week, Quanterix had 1 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Quanterix and 5 mentions for SiBone. SiBone's average media sentiment score of 0.45 beat Quanterix's score of 0.12 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTKB or QTRX?

In the previous week, Quanterix had 4 more articles in the media than Cytek Biosciences. MarketBeat recorded 6 mentions for Quanterix and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat Quanterix's score of 0.12 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer QTRX or OPTX?

Quanterix presently has a consensus price target of $4.00, indicating a potential upside of 30.29%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QTRX or OPTX more profitable?

Syntec Optics has a net margin of -10.95% compared to Quanterix's net margin of -71.86%. Quanterix's return on equity of -23.92% beat Syntec Optics' return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -71.86% -23.92% -17.66% Syntec Optics -10.95% -30.86% -12.35%

Does the media prefer QTRX or OPTX?

In the previous week, Quanterix and Quanterix both had 6 articles in the media. Syntec Optics' average media sentiment score of 0.35 beat Quanterix's score of 0.12 indicating that Syntec Optics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syntec Optics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LAB or QTRX?

In the previous week, Quanterix had 1 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Quanterix and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.58 beat Quanterix's score of 0.12 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRE or QTRX?

In the previous week, Prenetics Global had 2 more articles in the media than Quanterix. MarketBeat recorded 8 mentions for Prenetics Global and 6 mentions for Quanterix. Quanterix's average media sentiment score of 0.12 beat Prenetics Global's score of 0.00 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prenetics Global 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Quanterix (QTRX) Competitors

$3.07 -0.02 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.01 (+0.16%)

As of 07:59 PM Eastern

Compare

QTRX vs. SIBN, CTKB, OPTX, LAB, and PRE

Should you buy Quanterix stock or one of its competitors? MarketBeat compares Quanterix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quanterix include SiBone (SIBN), Cytek Biosciences (CTKB), Syntec Optics (OPTX), Standard BioTools (LAB), and Prenetics Global (PRE).

How does Quanterix compare to SiBone?

Quanterix (NASDAQ:QTRX) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

SiBone has higher revenue and earnings than Quanterix. SiBone is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.04	-$107.15M	-$2.36	N/A
SiBone	$200.93M	3.39	-$18.90M	-$0.39	N/A

In the previous week, Quanterix had 1 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Quanterix and 5 mentions for SiBone. SiBone's average media sentiment score of 0.45 beat Quanterix's score of 0.12 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SiBone has a net margin of -8.10% compared to Quanterix's net margin of -71.86%. SiBone's return on equity of -9.56% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-71.86%	-23.92%	-17.66%
SiBone	-8.10%	-9.56%	-7.06%

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quanterix has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Quanterix currently has a consensus price target of $4.00, indicating a potential upside of 30.29%. SiBone has a consensus price target of $23.00, indicating a potential upside of 49.64%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

SiBone beats Quanterix on 13 of the 16 factors compared between the two stocks.

How does Quanterix compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cytek Biosciences presently has a consensus price target of $5.69, indicating a potential upside of 40.43%. Quanterix has a consensus price target of $4.00, indicating a potential upside of 30.29%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cytek Biosciences is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Cytek Biosciences has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Cytek Biosciences has higher revenue and earnings than Quanterix. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A
Quanterix	$138.90M	1.04	-$107.15M	-$2.36	N/A

In the previous week, Quanterix had 4 more articles in the media than Cytek Biosciences. MarketBeat recorded 6 mentions for Quanterix and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat Quanterix's score of 0.12 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytek Biosciences has a net margin of -36.25% compared to Quanterix's net margin of -71.86%. Cytek Biosciences' return on equity of -10.07% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Quanterix	-71.86%	-23.92%	-17.66%

Summary

Cytek Biosciences beats Quanterix on 13 of the 16 factors compared between the two stocks.

How does Quanterix compare to Syntec Optics?

Quanterix (NASDAQ:QTRX) and Syntec Optics (NASDAQ:OPTX) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Quanterix presently has a consensus price target of $4.00, indicating a potential upside of 30.29%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Quanterix and Quanterix both had 6 articles in the media. Syntec Optics' average media sentiment score of 0.35 beat Quanterix's score of 0.12 indicating that Syntec Optics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syntec Optics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Syntec Optics has lower revenue, but higher earnings than Quanterix. Syntec Optics is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.04	-$107.15M	-$2.36	N/A
Syntec Optics	$28.08M	18.36	-$1.79M	-$0.08	N/A

Syntec Optics has a net margin of -10.95% compared to Quanterix's net margin of -71.86%. Quanterix's return on equity of -23.92% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-71.86%	-23.92%	-17.66%
Syntec Optics	-10.95%	-30.86%	-12.35%

Quanterix has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Syntec Optics has a beta of -0.82, meaning that its share price is 182% less volatile than the broader market.

86.5% of Quanterix shares are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Comparatively, 0.8% of Syntec Optics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Quanterix beats Syntec Optics on 8 of the 14 factors compared between the two stocks.

How does Quanterix compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Standard BioTools has higher earnings, but lower revenue than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	4.03	-$74.90M	$0.20	4.41
Quanterix	$138.90M	1.04	-$107.15M	-$2.36	N/A

Standard BioTools has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

In the previous week, Quanterix had 1 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Quanterix and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.58 beat Quanterix's score of 0.12 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Standard BioTools currently has a consensus target price of $1.35, suggesting a potential upside of 53.22%. Quanterix has a consensus target price of $4.00, suggesting a potential upside of 30.29%. Given Standard BioTools' higher possible upside, equities analysts plainly believe Standard BioTools is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Standard BioTools has a net margin of 73.46% compared to Quanterix's net margin of -71.86%. Standard BioTools' return on equity of -8.18% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Quanterix	-71.86%	-23.92%	-17.66%

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Standard BioTools beats Quanterix on 11 of the 14 factors compared between the two stocks.

How does Quanterix compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Prenetics Global had 2 more articles in the media than Quanterix. MarketBeat recorded 8 mentions for Prenetics Global and 6 mentions for Quanterix. Quanterix's average media sentiment score of 0.12 beat Prenetics Global's score of 0.00 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prenetics Global	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prenetics Global has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Prenetics Global has a net margin of -61.33% compared to Quanterix's net margin of -71.86%. Prenetics Global's return on equity of -19.61% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-61.33%	-19.61%	-15.33%
Quanterix	-71.86%	-23.92%	-17.66%

Prenetics Global has higher earnings, but lower revenue than Quanterix. Prenetics Global is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39M	3.51	-$37.71M	-$4.02	N/A
Quanterix	$138.90M	1.04	-$107.15M	-$2.36	N/A

25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Prenetics Global currently has a consensus target price of $32.33, indicating a potential upside of 67.97%. Quanterix has a consensus target price of $4.00, indicating a potential upside of 30.29%. Given Prenetics Global's stronger consensus rating and higher possible upside, equities research analysts clearly believe Prenetics Global is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Prenetics Global beats Quanterix on 10 of the 16 factors compared between the two stocks.

Get Quanterix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTRX vs. The Competition

Export

Metric	Quanterix	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$145.56M	$8.61B	$6.50B	$11.95B
Dividend Yield	N/A	2.50%	2.67%	5.61%
P/E Ratio	-1.30	16.10	24.65	23.63
Price / Sales	1.04	6.35	498.98	103.49
Price / Cash	N/A	17.40	43.05	54.72
Price / Book	0.48	3.54	10.43	6.70
Net Income	-$107.15M	$225.32M	$3.56B	$337.26M
7 Day Performance	-13.03%	-0.12%	-1.39%	-1.41%
1 Month Performance	8.48%	1.43%	0.86%	1.15%
1 Year Performance	-53.34%	-4.31%	19.42%	22.61%

Quanterix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTRX Quanterix	2.117 of 5 stars	$3.07 -0.6%	$4.00 +30.3%	-38.9%	$145.56M	$138.90M	N/A	460	News Coverage
SIBN SiBone	2.2775 of 5 stars	$14.97 -1.0%	$23.00 +53.6%	-17.7%	$670.56M	$200.93M	N/A	350	Gap Up
CTKB Cytek Biosciences	2.1184 of 5 stars	$4.04 -1.2%	$5.69 +40.8%	+16.0%	$528.20M	$204.17M	N/A	500	News Coverage
OPTX Syntec Optics	0.1984 of 5 stars	$11.91 +4.9%	N/A	+640.8%	$457.18M	$28.08M	N/A	3	News Coverage Short Interest Increase
LAB Standard BioTools	2.7337 of 5 stars	$0.80 -30.2%	$1.35 +68.1%	-17.9%	$448.92M	$86.26M	4.02	620	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTRX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quanterix (QTRX) Competitors

QTRX vs. SIBN, CTKB, OPTX, LAB, and PRE

How does Quanterix compare to SiBone?

Summary

How does Quanterix compare to Cytek Biosciences?

Summary

How does Quanterix compare to Syntec Optics?

Summary

How does Quanterix compare to Standard BioTools?

Summary

How does Quanterix compare to Prenetics Global?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX vs. The Competition

Quanterix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quanterix (QTRX) Competitors

QTRX vs. SIBN, CTKB, OPTX, LAB, and PRE

How does Quanterix compare to SiBone?

Which has higher valuation and earnings, QTRX or SIBN?

Does the media refer more to QTRX or SIBN?

Is QTRX or SIBN more profitable?

Do institutionals & insiders believe in QTRX or SIBN?

Which has more volatility & risk, QTRX or SIBN?

Do analysts recommend QTRX or SIBN?

Summary

How does Quanterix compare to Cytek Biosciences?

Do insiders and institutionals have more ownership in CTKB or QTRX?

Do analysts recommend CTKB or QTRX?

Which has more volatility and risk, CTKB or QTRX?

Which has higher earnings and valuation, CTKB or QTRX?

Does the media favor CTKB or QTRX?

Is CTKB or QTRX more profitable?

Summary

How does Quanterix compare to Syntec Optics?

Do analysts prefer QTRX or OPTX?

Does the media prefer QTRX or OPTX?

Which has higher valuation and earnings, QTRX or OPTX?

Is QTRX or OPTX more profitable?

Which has more volatility & risk, QTRX or OPTX?

Do insiders & institutionals believe in QTRX or OPTX?

Summary

How does Quanterix compare to Standard BioTools?

Which has preferable earnings and valuation, LAB or QTRX?

Which has more volatility and risk, LAB or QTRX?

Does the media prefer LAB or QTRX?

Do analysts prefer LAB or QTRX?

Is LAB or QTRX more profitable?

Do insiders and institutionals hold more shares of LAB or QTRX?

Summary

How does Quanterix compare to Prenetics Global?

Does the media prefer PRE or QTRX?

Which has more volatility & risk, PRE or QTRX?

Is PRE or QTRX more profitable?

Which has better earnings and valuation, PRE or QTRX?

Do insiders & institutionals believe in PRE or QTRX?

Do analysts prefer PRE or QTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX vs. The Competition

Quanterix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools